Olutasidenib, also known as FT-2102, is a small molecule drug that has been developed for the treatment of advanced solid tumors with specific mutations in the isocitrate dehydrogenase 1 (IDH1) enzyme. This enzyme is involved in cellular metabolism and mutations in IDH1 are known to contribute to the development of several types of cancer including gliomas, acute myeloid leukemia, and cholangiocarcinoma. Olutasidenib has shown promising results in early clinical trials and is currently undergoing further testing to determine its efficacy and safety.
Chemical name: The chemical name of Olutasidenib is N-[(cis)-3-ethyl-5-fluoro-7-methyl-8-oxo-2,3,4,5-tetrahydro-1,6-naphthyridin-6-yl]-2-(2-fluoro-4-methyl-5-(2-(2-(2,2,2-trifluoroethoxy)ethoxy)ethoxy)phenyl)acetamide.
Molecular formula: The molecular formula of Olutasidenib is C30H32F5N5O4.
Formula weight: The formula weight of Olutasidenib is 639.6 g/mol.
CAS No: The CAS number for Olutasidenib is 3887014-12-1.
Top ten keywords from Google and synonyms:
- Olutasidenib - FT-2102
- Isocitrate dehydrogenase 1 (IDH1) - metabolic enzyme
- Gliomas - brain tumor
- Acute myeloid leukemia - cancer affecting blood and bone marrow
- Cholangiocarcinoma - cancer of the bile ducts
- Mutations - genetic changes
- Clinical trials - testing of new drugs on human subjects
- Efficacy - effectiveness
- Safety - absence of harm or injury
- Side effects - unwanted effects of a medication or drug
Health benefits of this product: Olutasidenib has shown promise in early clinical trials for the treatment of advanced solid tumors with specific mutations in the IDH1 enzyme. In a phase I clinical trial, Olutasidenib demonstrated a favorable safety profile and resulted in partial or complete responses in patients with IDH1-mutant cholangiocarcinoma and glioma. These responses were maintained for several months, providing hope for patients with these difficult-to-treat cancers.
Potential effects: The mechanism of action of Olutasidenib is to inhibit the mutated IDH1 enzyme, which is involved in cellular metabolism and contributes to the development of certain cancers. By inhibiting this enzyme, Olutasidenib may be able to slow or stop the growth of tumors in patients with specific mutations in IDH1. In early clinical trials, Olutasidenib has shown efficacy in patients with IDH1-mutant cholangiocarcinoma and gliomas.
Product mechanism: The mechanism of action of Olutasidenib is to inhibit the mutated IDH1 enzyme, which is involved in the metabolism of cells. Mutations in IDH1 contribute to the development of certain types of cancer, including gliomas, acute myeloid leukemia, and cholangiocarcinoma. By inhibiting this enzyme, Olutasidenib may be able to slow or stop the growth of tumors in patients with these specific mutations in IDH1.
Safety: Olutasidenib has demonstrated a favorable safety profile in early clinical trials. In a phase I trial, the drug was well-tolerated and only mild to moderate adverse events were reported. The most common adverse events were nausea, diarrhea, and fatigue. There were no serious adverse events related to the drug and no dose-limiting toxicities were observed